Across the developed world, the sun's long reckoning with human skin is being counted in advance. By 2035, eight major markets will diagnose an estimated 263,000 melanoma cases annually — 34,000 more than today — with the United States carrying the heaviest burden and Australia bearing the highest rate per capita, a consequence of geography, biology, and the unforgiving physics of ultraviolet light. The rise is not sudden but steady, and health systems that read the forecast now may yet build the capacity to meet it with care rather than crisis.
Melanoma cases in major markets projected to surge 15% by 2035
Projected increase of 34,000 additional melanoma cases annually by 2035 across major markets will impact patient populations requiring treatment and care.
The combination of latitude, hemisphere position, and fair skin creates a perfect storm
Mark
Why is the US number so much larger than everywhere else, if Australia has the highest rate?
Mimi
Population. The US has 330 million people. Australia has 26 million. Even though Australians get melanoma at a much higher rate per capita, there are simply far more Americans, so the absolute number of cases is larger.
Mark
And that 15% increase—is that because more people are getting melanoma, or because we're diagnosing it better?
Mimi
Both, probably. UV exposure hasn't gone down. But the data shows most cases are caught at Stage 1, which suggests awareness campaigns are working. People are checking their skin, seeing doctors sooner.
Mark
So early detection is masking a worsening problem?
Mimi
Not masking it. More like softening the blow. The cases are still rising, but catching them early means fewer deaths, fewer advanced treatments. The problem is real, but we're responding to it faster.
Mark
What happens to a healthcare system when 34,000 new melanoma cases arrive every year?
Mimi
Dermatology becomes a bottleneck. Pathology labs get busier. Oncology services need more capacity. It's not dramatic, but it's relentless. You can't just add one clinic and call it solved.
Mark
Is there anything that could reverse this trend?
Mimi
Sustained, aggressive sun protection. But that's a generational shift. People would need to change behavior fundamentally, and UV exposure is baked into how we live—outdoor work, recreation, travel. The projections assume current behavior continues.
The Pulse
- A projected 15% global rise in melanoma cases by 2035 means 34,000 additional patients every year will need diagnosis, treatment, and long-term surveillance.
- The United States alone will account for more than 130,000 annual cases, placing enormous pressure on dermatology, pathology, and oncology services.
- Australia's incidence rate stands apart from every other wealthy nation — not from negligence, but from the compounding forces of latitude, hemisphere, and a predominantly fair-skinned population absorbing more intense UV radiation year-round.
- A quiet signal of progress runs beneath the alarming numbers: early-stage diagnoses dominate across all eight markets, suggesting decades of public awareness campaigns are catching melanoma before it becomes hardest to treat.
- Health systems face not a sudden shock but a slow, measurable tide — one that demands infrastructure investment now, while the window to prepare remains open.
Across the developed world, the sun's long reckoning with human skin is being counted in advance. By 2035, eight major markets will diagnose an estimated 263,000 melanoma cases annually — 34,000 more than today — with the United States carrying the heaviest burden and Australia bearing the highest rate per capita, a consequence of geography, biology, and the unforgiving physics of ultraviolet light. The rise is not sudden but steady, and health systems that read the forecast now may yet build the capacity to meet it with care rather than crisis.
By 2035, the eight largest markets — the United States, Canada, Australia, and five major European nations — will diagnose roughly 263,000 new melanoma cases annually, up from 229,000 today. That additional 34,000 patients each year will require diagnosis, treatment, and the sustained surveillance that follows a skin cancer diagnosis.
The United States will carry the greatest absolute burden, with more than 130,000 projected cases — a figure that dwarfs Canada's 14,000, Australia's 21,000, and the combined 88,000 across France, Germany, Italy, Spain, and the United Kingdom. But it is Australia's rate, not its raw count, that stands out most sharply. Adjusted for population, no other developed nation comes close. The reasons are geographic and biological: Australia's southern hemisphere position brings more intense ultraviolet radiation year-round, and its predominantly fair-skinned population carries heightened susceptibility. As GlobalData epidemiologist Robyn Jones put it, Australians aren't less careful — they're fighting harder physics.
One thread of cautious optimism runs through the projections. Across all eight markets, Stage 1 melanoma accounts for the largest share of diagnoses, pointing to the cumulative effect of public health campaigns and UV protection efforts. Early detection dramatically improves survival, meaning the rising case count may not translate into proportionally worse outcomes.
Still, the forecast describes a slow, predictable tide rather than a sudden crisis — and that distinction matters. Dermatology departments, pathology labs, and oncology services will all face growing demand. The time to build that capacity is now, while the trajectory is visible and the window to prepare remains open.
Melanoma is coming. Not tomorrow, but the trajectory is clear enough that health systems across the developed world are beginning to brace for it. By 2035, the eight largest markets—the United States, Canada, Australia, and five major European nations—will diagnose roughly 263,000 new cases of melanoma annually, up from 229,000 today. That's 34,000 additional patients every year, each one requiring diagnosis, treatment, and the long surveillance that follows a skin cancer diagnosis.
The United States will bear the largest share of this burden. American dermatologists and oncologists can expect to see more than 130,000 new melanoma cases by the middle of the next decade, according to analysis from GlobalData. That figure dwarfs every other market. Canada will see around 14,000 cases. Australia, despite having a far smaller population, will record approximately 21,000. The five major European markets combined—France, Germany, Italy, Spain, and the United Kingdom—will account for about 88,000 cases.
What makes Australia's numbers particularly striking is not the absolute count but the rate. When you adjust for population size, Australia's melanoma incidence far exceeds that of any other developed nation. The explanation is geographic and biological. Australia sits in the southern hemisphere, closer to the equator than most comparable wealthy nations, which means more intense ultraviolet radiation reaches the ground year-round. The country's population is also predominantly fair-skinned, a demographic factor that significantly elevates melanoma risk. UV exposure, the report makes clear, remains the dominant risk factor driving these projections.
Robyn Jones, an epidemiologist at GlobalData, framed the Australian pattern this way: the combination of latitude, hemisphere position, and a population genetically vulnerable to sun damage creates a perfect storm for skin cancer. It's not that Australians are more careless about sun protection—it's that they're fighting harder physics.
One piece of the forecast carries a note of cautious optimism. Across all eight markets, Stage 1 melanoma—the earliest, most treatable form—accounts for the largest share of diagnosed cases. This suggests that public health campaigns warning people to watch their skin, to see a doctor about changing moles, to understand the ABCDEs of melanoma detection, are working. Jones attributed this pattern to decades of awareness efforts and multi-layered interventions designed to reduce UV exposure. When people catch melanoma early, survival rates climb dramatically. The high proportion of early-stage diagnoses means that despite the rising case count, outcomes may not deteriorate proportionally.
Still, 34,000 additional cases annually represents a real strain on healthcare infrastructure. Dermatology departments will need more capacity. Pathology labs will process more biopsies. Oncology services will manage more patients through treatment and follow-up. The projection is not a crisis in the sense of a sudden shock, but rather a slow, predictable tide that health systems must prepare for now, while there is still time to build the necessary resources and expertise.
Notable Quotes
The discrepancy between incidence rates of melanoma in Australia and those in all other markets may be explained by a combination of its location on the southern hemisphere, its proximity to the equator, and a considerable number of its population with fair skin.— Robyn Jones, epidemiologist at GlobalData
High rates of early-stage diagnoses reflect growing public awareness of melanoma and the risks associated with UV exposure, likely attributed to public health protection efforts aimed at increasing awareness of how melanoma presents, alongside multi-pronged interventions to curb UV exposure.— Robyn Jones, epidemiologist at GlobalData
Want the full story?
Read the original at Healthcare Asia Magazine ↗
General News